Is India suffering from drug pipeline deficit?

Updated on 15 January 2013

Dr Rajesh Gokhale, director, Institute of Genomics and Integrative Biology (IGIB) is quite optimistic about the drug discovery efforts being put into various areas. He opined that systems biology is quite relevant to the drug discovery. Citing an example he said, "Isoniazid, an antibiotic that is used to treat tuberculosis targets 16 proteins on Mycobacterium tuberculorsis. The biggest challenge is taking up the conservative model rather than alternative model, where no target is defined."

In order to capitalize on its competitive advantages and remain ahead of competing markets, India must take active steps to attract research investment. These include the introduction of self-financing and revenue-generating fiscal incentives, encouragement of capacity building measures, continuing regulatory reform, and initiatives in specific research oriented education and training. The timely implementation of these measures will be critical to build a pipeline or what we may call a lifeline for the future needs of healthcare industry.

1 3 Next

1Comment

Comment 1 - 1 of 1

Suhasini Bhatnagar 22 January 2013 at 06 PM

I completely disagree with your idea that there is a deficit.Infact i believe there is an excess. Infact I am not wrong in saying that the amount of natural medicines present in India is far more than anywhere else in the world.we may be lacking the chemicals to try out in a set systeem but my argument is why do we neeed a set system at all.We have so many religious books

Reply

Leave a Reply

Post Comment

Special Features

Survey Box

Women in Bioscience

Do you think women and men are equal achievers in the bioscience industry?

Send this article by email

X